Novel treatments target type-2 diabetes

P and T

Volumn 41, Issue 10, 2016, Pages 650-653

  Fellner, Chris ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIXISENATIDE; METFORMIN; PIOGLITAZONE; SEMAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA;

ACUTE CORONARY SYNDROME; BLINDNESS; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG GLUCURONIDATION; FAMILY HISTORY; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; LEG AMPUTATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL INACTIVITY; PREGNANCY DIABETES MELLITUS; RISK FACTOR; VOMITING;

EID: 84991632778     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (22)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. October 24, 2014. Available at: www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed July 11, 2016.
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2010;35: 1333–1346.
3. International Diabetes Federation. Risk factors. 2015. Available at: www.idf.org/ about-diabetes/risk-factors. Accessed July 11, 2016.
4. American Diabetes Association. Standards of medical care in diabetes– 2015. Diabetes Care 2015;38(suppl 1): S1–S90.
5. Cleveland Clinic. Treatments and procedures: glycolated hemoglobin test (A1c). 2015. Available at: http://my.clevelandclinic.org/health/diseases_conditions/hic_Diabetes_Basics/hic_Working_with_Your_Diabetes_Health_Care_Team/hic_Glycolated_Hemoglobin_Test_HbA1c_for_Diabetes. Accessed July 11, 2016.
6. Pernicova I, Korbonits M. Metformin— mode of action and clinical implications for diabetes and cancer. Nature Rev Endocrinol 2014;10:143–156.
7. Sanofi. Sanofi receives FDA approval of Adlyxin for treatment of adults with type 2 diabetes. July 28, 2016. Available at: http://mediaroom.sanofi.com/%E2%80%8Bsanofi-receives-fdaapproval-of-adlyxintm-for-treatment-ofadults-with-type-2-diabetes. Accessed August 2, 2016.
8. Cuaron J, Gburcik V, Prabhakar B, et al. PharmaPoint: Type 2 Diabetes—Global Drug Forecast and Market Analysis to 2025. New York, New York: GlobalData; June 2016.
9. Pfizer. Merck and Pfizer announce two pivotal phase 3 studies for ertugliflozin, an investigational SGLT-2 inhibitor, met primary endpoints, showing significant A1C reductions in patients with type 2 diabetes. July 11, 2016. Available at: www.pfizer.com/news/press-release/press-releasedetail/merck_and_pfizer_announce:two_pivotal_phase_3_studies_for_ertugliflozin_an_investigational_sglt_2_inhibitor_met_primary_endpoints_showing_significant_a1c_reductions_in_patients_with_type_2_diabetes. Accessed July 12, 2016.
10. Food and Drug Administration. Sodiumglucose cotransporter-2 (SGLT2) inhibitors. June 16, 2016. Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm446852.htm. Accessed July 12, 2016.
11. Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos 2013;41:445–456.
12. Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. May 15, 2015. Available at: www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed July 12, 2016.
13. Novo Nordisk. Novo Nordisk files for regulatory approval of “faster-acting insulin aspart” in the U.S. December 9, 2015. Available at: http://press.novonordisk-us.com/2015-12-09-Novo-Nordisk-filesfor-regulatory-approval-of-faster-acting-insulin-aspart-in-the-U-S. Accessed July 12, 2016.
14. NovoNordisk. Novo Nordisk completes phase 3a trials comparing fasteracting insulin aspart with NovoRapid in people with type 1 and type 2 diabetes. March 25, 2015. Available at: www.novonordisk.com/bin/getPDF.1906174.pdf. Accessed July 12, 2016.
15. Intarcia Therapeutics, Inc. ITCA 650. 2016. Available at: www.intarcia.com/pipelinetechnology/itca-650.html. Accessed July 12, 2016.
16. Intarcia Therapeutics, Inc. FREEDOM clinical trial program. 2016. Available at: www.intarcia.com/pipeline-technology/freedom.html. Accessed July 12, 2016.
17. Intarcia Therapeutics, Inc. Intarcia announces two positive phase 3 trials for ITCA 650 in type 2 diabetes: FREEDOM- 1 and FREEDOM-1 High Baseline (HBL) study results. October 1, 2014. Available at: www.intarcia.com/media/ press-releases/2014-oct-1-phase-3.html. Accessed July 12, 2016.
18. Intarcia Therapeutics, Inc. Intarcia presents FREEDOM-2 trial results in type 2 diabetes demonstrating clinically meaningful superiority and sustained glucose control and weight reduction for ITCA 650 versus Januvia: oral presentation at ADA 76th scientific sessions. June 12, 2016. Available at: www.intarcia.com/media/press-releases/2016-june-12-freedom-2-trial-results-in-type-2-diabetes.html. Accessed July 12, 2016.
19. Intarcia Therapeutics, Inc. Intarcia announces successful cardiovascular safety results in phase 3 FREEDOMCVO trial for ITCA 650, an investigational therapy for type 2 diabetes. May 6, 2016. Available at: www.intarcia.com/media/press-releases/2016-may-6-cardiovascular-safety.html. Accessed July 12, 2016.
20. Novo Nordisk. Novo Nordisk to initiate phase 3a development of oral semaglutide, a once-daily oral GLP-1 analogue. August 26, 2015. Available at: www.novonordisk.com/media/news-details.1947638.html. Accessed July 13, 2016.
21. ClinicalTrials.gov. Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes (PIONEER 3). NCT02607865. May 26, 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02607865. Accessed July 13, 2016.
22. Novo Nordisk. Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes. June 12, 2016. Available at:www.novonordisk.com/media/news-details.2019820.html. Accessed July 13, 2016.